KRAS and neoplasm: Prior to the investigation of KRAS-mutated ctDNA in plasma, KRAS assessment was performed in tumor tissues of 61 PDAC patients using RASKET with a sensitivity of 1–5% and ddPCR with a sensitivity of 0.01–0.1%.